Why the study?
Does ICRF-187 reduce doxorubicin-induced cardiotoxicity in pediatric sarcoma patients?
Does ICRF-187 reduce doxorubicin-induced cardiotoxicity in pediatric sarcoma patients?
ICRF-187 reduces the risk of short-term subclinical cardiotoxicity in pediatric sarcoma patients receiving doxorubicin without compromising oncologic efficacy.
No takes yet. Share an insight, caveat, or question.
Supports ICRF-187 for cardioprotection in pediatric doxorubicin regimens; extends RCT evidence to sarcoma without oncologic compromise.
Wexler et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: